(Q37362175)

19 August 2017

Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy (English)

1 reference

19 August 2017

0 references

J C Becker

1

1 reference

19 August 2017

N Varki

2

1 reference

19 August 2017

S D Gillies

3

1 reference

19 August 2017

K Furukawa

4

1 reference

19 August 2017

R A Reisfeld

5

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 December 1996

1 reference

Journal of Clinical Investigation

19 August 2017

1 reference

19 August 2017

98

1 reference

19 August 2017

12

1 reference

19 August 2017

2801-2804

1 reference

An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Interleukin-2 in cancer treatment: disappointing or (still) promising? A review

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Paracrine cytokine adjuvants in cancer immunotherapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Human recombinant interleukin-2 as an experimental therapeutic

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

T-cell memory: the connection between function, phenotype and migration pathways

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Lymphocyte responses and cytokines

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Recent developments in immunotoxin therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Gene transfer as cancer therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Ly-6C is a marker of memory CD8+ T cells.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Surveillance, latency and the two levels of MCA-induced tumor immunogenicity

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507746

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

2 October 2018

1 reference

12 December 2020

High-level expression of chimeric antibodies using adapted cDNA variable region cassettes

1 reference

12 December 2020

Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody

1 reference

12 December 2020

Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses

1 reference

12 December 2020

Applications of monoclonal antibodies in clinical oncology

1 reference

12 December 2020

Identifiers

DOI

10.1172/JCI119107

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

8981927

1 reference